PUS7

Across TCGA pan-cancer cohorts, PUS7 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PUS7 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PUS7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PUS7 expression acts as an unfavorable survival marker.

KIRP, BLCA, and LUSC are the cancer types where PUS7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.176	0.885	<.001	24	view →
BLCA	OS	Median	III,IV	0.130	0.684	<.001	24	view →
LUSC	OS	Median	All	0.182	0.676	.002	21	view →
LUAD	OS	Median	All	0.216	0.835	<.001	18	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	18	view →
LIHC	OS	Median	All	0.008	0.777	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →
STAD	DFS	Median	All	0.198	0.587	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PUS7–KIRP (OS)

Open the KIRP breakdown →